Balsalazide

Balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: Balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older.

What it is used for

Limitations of Use

Safety and effectiveness of balsalazide disodium capsules beyond 8 weeks in pediatric patients 5 years to 17 years of age and 12 weeks in adults have not been established.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in labeling:

Renal Impairment
Mesalamine-Induced Acute Intolerance Syndrome
Hypersensitivity Reactions
Hepatic Failure
Severe Cutaneous Adverse Reactions
Upper Gastrointestinal Tract Obstruction
Photosensitivity
Nephrolithiasis

Who should not take it

Balsalazide disodium capsules are contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or to any of the components of balsalazide disodium capsules or balsalazide metabolites.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Balsalazide; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/balsalazide
APA 7th: sofidex. (2026, August 2). Balsalazide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/balsalazide
AMA 11th: Balsalazide. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/balsalazide

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.